New research in the FASEB Journal suggests the protein Ddi 1 from Leishmania parasites is sensitive to anti-HIV inhibitors and could be target for malaria and other parasitic diseases
Scientists have discovered that drugs used to treat HIV may also one day become lifesaving drugs targeted at parasitic diseases such as leishmaniasis and malaria. According to new research published in The FASEB Journal (http://www.fasebj.org), scientists have identified the target of action for some anti-HIV drugs with known abilities to kill serious pathogenic parasites. While scientists have long known that these HIV drugs can kill parasites, exactly how they work was previously unknown. Researchers discovered that a particular protein called Ddi 1 from Leishmania parasites is sensitive to anti-HIV inhibitors. This research could one day significantly change the treatment of parasitic diseases.
"People in developing countries can be exposed to parasitic diseases such as malaria and leishmaniasis that can kill millions of people, so new and effective drugs are urgently needed to combat these infections," said Colin Berry, Ph.D., a researcher involved in the work from the Cardiff School of Biosciences at Cardiff University in Cardiff in the United Kingdom. "The use of existing anti-HIV agents has indicated that there is a potential target in some parasites and by identifying the protein responsible, we hope to exploit this weakness in the parasite to develop new and effective therapeutics to combat these devastating diseases."
Scientists studied yeast that lacked the Ddi 1 protein and found that high levels of proteins were secreted. The addition of the Leishmania Ddi 1 protein returned the yeast to normal low secretion levels until HIV proteinase inhibitors were added. These inhibitors blocked the ability of Leishmania Ddi 1 to reduce secretions and showed that the Ddi 1 protein interacted with the drugs. Additionally, when researchers used human Ddi 1, they identified drugs that were good at blocking the activity of the Leishmania protein, but which were much weaker against the human equivalent, suggesting that possible side effects in a future drug could be reduced. Study data support the potential use of this class of compounds for leishmaniasis, but do not yet support the use of existing marketed compounds in a clinical context. The potency of the existing compounds indicates that they may be a useful start point for further exploratory chemistry.
"Like HIV, parasitic diseases have been and still are a serious threat to human health world-wide," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Millions die each year from these maladies and we desperately need new drugs. How fortuitous that agents designed against one killer, HIV, may now be turned against parasitic diseases such as leishmaniasis and malaria."
###
Receive monthly highlights from the FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx.
The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB). The journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information.
FASEB comprises 23 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve—through their research—the health, well-being and productivity of all people. FASEB's mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Rhian E. White, David J. Powell, and Colin Berry. HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites. FASEB J May 2011 25:1729-1736; doi:10.1096/fj.10-178947 ; http://www.fasebj.org/content/25/5/1729.abstract
This should be really good news, if they (big pharma) don't drag their feet since profits are not generated swiftly by millions of poor people.
Anyone that believes that capitalism is the best system for everything is rich and brainwashed.
Big pharma doesn't do charity until it is very cheap and serves corporate insterests somewhere. (Like the Central American and Mexican plantation workers getting free ivermectin for onchocerca volvulus....cheap for big pharma and corporations that donate or pay.) Malaria is beginning to bother the oil companies in Africa, it may finally get some real attention.
These HIV drugs already have safety profiles and should be relatively easy to tweak and get through regulatory bodies to use for parasitic diseases. We'll see how quckly it happens.
the anti-protease inhibitor drugs, for one example Nefinavir is not that expensive to buy online which is tempting to try but as it appears there is no concise research to describe how Aids drugs and to which parasite species these drugs could disable parasites.
If comprehensive research was out there I would get my visa out without delay otherwise it's like shooting in the dark and I've done enough of that for nearly a year.
The study you posted only mentioned leishmaniasis and malaria. Unless you know without a doubt that that's what you're suffering from, I would advise against trying antiretroviral drugs. It is very off-label and hasn't been studied enough, plus the side effects of antiretroviral drugs are known to be extreme.
the link I posted shows some mega side effects and there is no research done on other parasite species, apart from those you mentioned above, is not enough to warrant the risk.
Images Description Human Parasites Parasites Cleanse Rules
Home
Scientists show that HIV drugs can also target tropical parasites 
